← Back

Wire · opportunities

Biostream Urine Test for Normal Pressure Hydrocephalus Earns FDA Breakthrough Designation

Published

20 November 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at clpmag.com →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

Biostream's urine test for idiopathic normal pressure hydrocephalus (iNPH) has earned FDA Breakthrough Device Designation, accelerating priority review and engagement to aid diagnosis and differentiating iNPH from Alzheimer’s and other conditions. The test uses a protein panel and algorithm on urine samples, targeting patients 60 and older with symptoms, with clinical validation planned in US centers in 2027.

This Wire brief sits within Fusion42's coverage of Diagnostics.

◆ ◆ The Wire takeaway

You can position your neurological diagnostic startup to leverage the FDA's priority path for tests distinguishing treatable neuro conditions. This opens faster routes for innovation beyond invasive methods and sets a new bar for noninvasive biomarkers.

◆ Coverage

1 source · 20 Nov 2026

◆ Related on Wire

◆ Topics

Diagnosticsfda-breakthroughdiagnosticsneurologyurine-testalzheimersbiotechnology